Impact and indication of early systemic corticosteroids for very severe community-acquired pneumonia

International Journal of General Medicine

Volumn 6, Issue , 2013, Pages 693-701

  Ugajin, Motoi ^a   Yamaki, Kenichi ^a   Hirasawa, Natsuko ^a   Kobayashi, Takanori ^a   Yagi, Takeo ^a  

^a Ichinomiya Nishi Hospital   (Japan)

Author keywords

Community acquired pneumonia; Corticosteroids; Initial antibiotics; Intensive care; Mortality; Pneumonia severity index

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CLINDAMYCIN; CORTICOSTEROID; DEXAMETHASONE; METHYLPREDNISOLONE; METICILLIN; NITROGEN; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UREA;

ACINETOBACTER BAUMANNII; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIUM DETECTION; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG INDICATION; EARLY INTERVENTION; ENTEROCOCCUS; ESCHERICHIA COLI; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE; JAPAN; KLEBSIELLA PNEUMONIAE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PNEUMONIA SEVERITY INDEX; PROSPECTIVE STUDY; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; SERRATIA MARCESCENS; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

EID: 84883191744     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S49275     Document Type: Article

References (30)

1. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest. 1995; 107(5):1342-1349.
2. Montón C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med. 1999;27(9):1745-1753.
3. Annane D, Bellissant E, Bollaert PE, etal. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009;301(22):2362-2375.
4. Sligl WI, Milner DA, Sundar S, Mphatswe W, Majumdar SR. Safety and efficacy of corticosteroids for the treatment of septic shock: A systematic review and meta-analysis. Clin Infect Dis. 2009;49(1):93-101.
5. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J. 2007;30(5):951-956.
6. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-982.
7. Fernández-Serrano S, Dorca J, Garcia-Vidal C, etal. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15(2):R96.
8. Meijvis SC, Hardeman H, Remmelts HH, etal. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023-2030.
9. Mikami K, Suzuki M, Kitagawa H, etal. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185(5):249-255.
10. Fine MJ, Auble TE, Yealy DM, etal. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.
11. Oken MM, Creech RH, Tormey DC, etal. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
12. Miyashita N, Matsushima T, Oka M. Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med. 2006;45(7):419-428.
13. Jung C, Inder WJ. Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust. 2008;188(7):409-413.
14. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349.
15. Martínez R, Menéndez R, Reyes S, etal. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J. 2011;37(2):393-399.
16. Sibila O, Agustí C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J. 2008;32(2):259-264.
17. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993;104(2): 389-392.
18. Chen Y, Li K, Pu H, Wu T. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2011;16(3):CD007720.
19. Confalonieri M, Urbino R, Potena A, etal. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242-248.
20. Aujesky D, Auble TE, Yealy DM, etal. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005;118(4):384-392.
21. Valencia M, Badia JR, Cavalcanti M, etal. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest. 2007;132(2):515-522.
22. Ugajin M, Yamaki K, Iwamura N, Yagi T, Asano T. Blood urea nitrogen to serum albumin ratio independently predicts mortality and severity of community-acquired pneumonia. Int J Gen Med. 2012;5:583-589.
23. Loisa P, Parviainen I, Tenhunen J, Hovilehto S, Ruokonen E. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Crit Care. 2007;11(1):R21.
24. Bossa F, Fiorella S, Caruso N, etal. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol. 2007;102(3): 601-608.
25. Steinberg KP, Hudson LD, Goodman RB, etal; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354(16): 1671-1684.
26. Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3(1):17-21.
27. Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. 2011;13(4):R139.
28. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol. 1998;82(6):704-708.
29. Salluh JI, Bozza FA, Soares M, etal. Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity. Chest. 2008;134(5):947-954.
30. Kolditz M, Halank M, Schulte-Hubbert B, Höffken G. Adrenal function is related to prognosis in moderate community-acquired pneumonia. Eur Respir J. 2010;36(3):615-621.